Heat Biologics, Inc. (NASDAQ: HTBX) announced new preclinical findings on its COVID-19 vaccine, published in Frontiers in Immunology. The results demonstrate significant spike-specific CD8+ and CD4+ T-cell memory responses in animal models at 30 and 60 days post-vaccination. These findings underscore the potential of the vaccine to induce durable immunity through tissue-resident memory T-cells, which may enhance protection against respiratory viruses. CEO Jeff Wolf expressed excitement over these results, highlighting the vaccine's promise for long-lasting immune responses.
Heat Biologics (NASDAQ:HTBX) announced that its CEO, Jeff Wolf, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 21, 2021, at 11:30 a.m. EST. The presentation will be available via live webcast for registered conference attendees and institutional investors. A replay will be accessible on Heat's website shortly after the event. Heat Biologics is focused on developing first-in-class therapies to modulate the immune system, with its gp96 platform targeting cancer and COVID-19.
Heat Biologics, a clinical-stage biopharmaceutical company, has transferred its gp96-based COVID-19 vaccine cell line, ZVX-60, to Waisman Biomanufacturing. This transfer marks the beginning of the manufacturing process for ZVX-60, aimed at enhancing protection against COVID-19, either as a standalone vaccine or in combination with others. CEO Jeff Wolf highlighted this as a key milestone, noting positive recent data that demonstrates ZVX-60's effectiveness. The company anticipates moving ZVX-60 into human clinical trials soon.
Heat Biologics (NASDAQ:HTBX) has appointed William Ostrander as Chief Financial Officer, effective January 4, 2021. With over 20 years of financial management experience, he previously served as Vice President of Finance since September 2019. CEO Jeff Wolf praised Ostrander's contributions in strengthening the company's financial position, noting over $117 million in cash and short-term investments at the end of Q3 2020. The company is focused on developing innovative therapies, including a COVID-19 vaccine and multiple oncology candidates.
Heat Biologics (NASDAQ:HTBX) will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 am ET for 90 days. Heat Biologics is focused on developing first-in-class therapies to modulate the immune system, with multiple oncology candidates and a COVID-19 vaccine in development. Their gp96 platform aims to activate immune responses against cancer. For more information, visit Heat's investor relations page.
Heat Biologics, Inc. (NASDAQ:HTBX) has successfully completed the gp96-based COVID-19 vaccine cell line, ZVX-60, aimed at enhancing protection alongside other vaccines. Developed in collaboration with the University of Miami, early data shows a robust immune response against SARS-CoV-2's Spike protein, indicating effective T-cell activation. The company is now moving towards manufacturing and planning for first-in-human Phase 1 trials. CEO Jeff Wolf expressed optimism about ZVX-60's potential as an adjunct vaccine, following encouraging Phase 3 results from other developers.
Heat Biologics (NASDAQ: HTBX) announced a 1-for-7 reverse stock split, effective December 11, 2020, to meet Nasdaq minimum bid price requirements. This will reduce shares from approximately 159.8 million to 22.8 million. CEO Jeff Wolf stated the split aims to enhance market visibility and compliance, while noting the company has over $113 million in cash. Shareholders approved this action during a February 2020 meeting. Adjustments will be made to outstanding options and warrants accordingly.
Heat Biologics (NASDAQ:HTBX) recently provided updates on its oncology and COVID-19 vaccine programs for the third quarter ended September 30, 2020. The company holds over $117 million in cash and short-term investments. Key highlights include promising clinical data for HS-110 in lung cancer and advancements in PTX-35 for solid tumors. Preclinical data for its gp96-based COVID-19 vaccine shows strong T-cell responses. Financially, the company reported a net loss of $8.9 million, with research and development expenses at $3.2 million.
Heat Biologics (NASDAQ: HTBX) has been granted a new US patent (No. 10,780,161) related to its gp96 platform combined with Inducible T cell Co-stimulator (ICOS). This innovation aims to enhance immunity against tumors and viral infections, specifically targeting immunosuppressive tumor environments. Notably, pre-clinical studies indicate potential efficacy in treating COVID-19, generating critical CD8+ T cells. CEO Jeff Wolf emphasized the competitive edge of this single therapy approach over conventional antibody treatments, which may reduce systemic toxicity and costs.
Heat Biologics (NASDAQ:HTBX) announced that CEO Jeff Wolf will participate in a virtual panel titled, New Approaches to COVID-19: Hidden Breakthroughs, on September 10, 2020, at 1:00 p.m. ET. The discussion features leaders from biopharmaceutical companies exploring solutions to the COVID-19 pandemic. Heat Biologics is focused on developing immune system therapies, including a COVID-19 vaccine and various oncology candidates.